The Administrative Demands of Brain Tumor Care
Neuro-oncology patients face a unique convergence of clinical complexity and administrative burden. A patient diagnosed with glioblastoma multiforme (GBM) will typically undergo surgical resection, followed by concurrent radiation and temozolomide chemotherapy (the Stupp protocol), followed by adjuvant chemotherapy cycles, MRI surveillance at defined intervals, and—for eligible patients—clinical trial enrollment and participation. Each phase generates authorization requirements, scheduling logistics, and documentation obligations that accumulate throughout the care continuum.
According to the Society for Neuro-Oncology (SNO), the average GBM patient generates 47 discrete administrative interactions in the first year of treatment—encompassing insurance authorizations, scheduling coordination, laboratory coordination, imaging orders, and clinical documentation. For a neuro-oncology program managing 80 to 150 active patients, this creates a continuous administrative workload that exceeds the capacity of standard oncology coordination teams without dedicated support.
Multimodal Treatment Scheduling
Brain tumor patients receiving concurrent chemoradiation must have radiation therapy, chemotherapy administration, and laboratory monitoring appointments coordinated across multiple departments or facilities simultaneously. VAs trained in neuro-oncology scheduling manage the synchronization of radiation oncology appointments, infusion center slots, pre-treatment labs, and neurosurgery follow-up visits—ensuring the care sequence proceeds according to the clinical protocol without scheduling gaps that delay treatment.
During adjuvant chemotherapy cycles (typically 28-day cycles), VAs track cycle timing, schedule administration appointments, ensure pre-cycle lab orders are placed and resulted before infusion dates, and communicate cycle calendars to patients and caregivers. For patients receiving bevacizumab—an anti-VEGF agent commonly used in recurrent GBM—infusion scheduling must align with MRI surveillance timing, adding another coordination layer.
Chemotherapy Prior Authorization: A Recurring High-Stakes Process
Temozolomide, bevacizumab, lomustine, and other neuro-oncology agents are subject to prior authorization at first use and often at cycle renewals. Prior authorizations for bevacizumab—which carries annual costs exceeding $60,000 per patient—are particularly rigorous, with payers requiring documentation of GBM diagnosis, prior treatment failure, performance status assessment, and in some cases radiographic progression per RANO criteria.
VAs managing neuro-oncology PA workflows maintain payer-specific documentation templates, coordinate with medical oncology and neuroradiology for imaging reports supporting medical necessity, submit complete packages, and manage appeal processes when denials are issued. The cost of a single chemotherapy authorization denial—in both revenue loss and treatment delay—vastly exceeds the cost of dedicated VA support.
Dr. Anita Krishnamurthy, neuro-oncologist at a comprehensive cancer center in Seattle, noted in a 2025 SNO Annual Meeting abstract: "We reduced our bevacizumab authorization delay from 11 days to 4 days after deploying a VA to own PA submissions. That delay reduction has direct clinical implications for patients with active disease progression."
Clinical Trial Enrollment Support
Neuro-oncology programs at academic and community cancer centers are major sites for brain tumor clinical trials, but trial enrollment logistics are notoriously burdensome. Eligibility screening requires reviewing labs, imaging, pathology, and prior treatment records; informed consent processes require document management and tracking; and baseline assessment scheduling must align with treatment start windows.
VAs provide critical support in the enrollment process without compromising the regulatory integrity that clinical coordinators must maintain. They conduct pre-screening outreach to identify potentially eligible patients, coordinate baseline assessment scheduling, distribute and track pre-consent materials, and manage logistical communications with patients and families. These tasks—clearly administrative in nature—free research coordinators for protocol-specific responsibilities and FDA/IRB-required documentation.
Imaging Surveillance and MRI Coordination
Post-treatment surveillance MRI is the cornerstone of neuro-oncology response assessment, but coordinating surveillance imaging—typically every two months in active treatment and every three months in maintenance—requires proactive scheduling and authorization management. VAs track each patient's MRI schedule, place orders in advance, coordinate radiology appointments, obtain imaging authorizations from payers, and ensure results are routed to the treating oncologist before the next clinic visit.
For programs monitoring patients on clinical trials, MRI timing must align precisely with protocol-specified assessment windows. VAs manage this tracking against trial calendars, flagging upcoming imaging requirements to the research team.
Neuro-oncology programs looking to reduce treatment coordination delays, improve clinical trial enrollment throughput, and manage the administrative burden of high-complexity oncology care can explore trained VA solutions through Stealth Agents.
Sources
- Society for Neuro-Oncology, "Administrative Burden in Brain Tumor Care," SNO Annual Meeting Abstract, 2025
- National Cancer Institute, "GBM Treatment Landscape and Clinical Trial Enrollment," 2025
- American Medical Association, "Prior Authorization in Oncology," 2024
- Medical Group Management Association, "Oncology Practice Benchmarking," 2025
- Journal of Neuro-Oncology, "Care Coordination in Glioblastoma Management," 2025